The World Health Organization (WHO) has stated that more scientific evidence is needed before immunomodulators and host-directed therapies can be included in clinical trials for Bundibugyo Virus Disease (BVD). Current knowledge is largely based on research involving the Ebola virus, which is not sufficient to guide treatment decisions for BVD.

WHO’s Technical Advisory Group on Therapeutics Prioritization (TAG-TP) emphasized the need to collect high-quality clinical data from patients infected with the Bundibugyo virus. This includes studying immune responses, viral load, inflammation, organ damage, and blood clotting markers to better understand how the disease progresses.

Click here to join our WhatsApp channel here

The organization warned that some immunomodulatory treatments could be beneficial or harmful depending on the stage of illness, making careful patient selection and timing of treatment essential. WHO also highlighted the importance of generating evidence from animal studies to help identify the most promising therapies for future clinical trials.

The recommendations aim to support the safe development of effective treatments while minimizing risks for patients participating in Bundibugyo virus disease research.

Also read: Regional Hearing Care Gap Demands Stronger Screening and Public Health Support